TipXX

TipXX is a chemical compound with the molecular formula C20H26N2O2. It is a synthetic cannabinoid, a class of psychoactive compounds that are structurally related to cannabinoids found in the cannabis plant. TipXX was first synthesized in 2010 by a research group led by Dr. John W. Huffman at the University of California, San Diego. The compound is known for its potent psychoactive effects, with a potency approximately 10 times greater than delta-9-tetrahydrocannabinol (THC), the primary psychoactive compound in cannabis. TipXX is a full agonist at the cannabinoid CB1 receptor, meaning it binds to and activates this receptor with high affinity. It is also a partial agonist at the CB2 receptor. Due to its potent effects and lack of selectivity, TipXX is not approved for medical use and is considered a controlled substance in many jurisdictions. Its use is associated with a range of adverse effects, including anxiety, paranoia, and hallucinations. Research on TipXX is ongoing, with studies exploring its potential therapeutic applications and mechanisms of action. However, due to its psychoactive properties, the focus of much of this research is on understanding and mitigating its adverse effects.